Epistem has validated a range of tumour cell lines for subcutaneous xenografting and can develop novel xenograft models using proprietary or commercially available cell lines. Novel therapeutic agents can be administered via standard methods as well as more specialist routes such as intratumoral and minipumps. Combination therapies using chemotherapy and/or radiotherapy can be applied to these xenograft models.
As well as tumour volume, readouts obtained by histology, immunohistochemistry, FACS and biomarker analysis, including Epistem's proprietary plucked hair biomarker platform, are available.
The effect of a novel therapeutic agent on cancer stem cell populations can be assessed ex vivo using Epistem's Cancer Stem Cell Assay. Angiogenesis can also be investigated using Epistem's highly specialised in vivo assays.
Xenograft Model Description
Cells are engrafted and tumours develop. Novel therapeutic agents are administered via the specified route.
Epistem's Validated Cell Lines:
Colon: HCT8, HCT 15, HCT116, HT29, LS174T, Colo 205, LoVo, SW620, WiDr, DLD-1
Pancreas: BxPC-3, MiaPaca-2, Panc-1
SCC H&N: FaDu
Prostate: PC3, LNCap, DU145
Lung: Calu-6, A549
Breast: MCF7, BT474, MDA-MB-231
Syngeneic: CT26, 4T1, B16
Other cell lines can be developed on request. Contact us.
- Tumour volume
- Histology and immunohistochemistry
- FACS analysis
- Gene expression analysis
- Plucked hair biomarker analysis
- Biomarker identification and validation
Further readouts available on request.